EuResist update Francesca Incardona Arevir-EuResist International - PowerPoint PPT Presentation

EuResist update Francesca Incardona Arevir-EuResist International meeting Cologne 8-9 May 2015

 EIDB  ENGINE RETRAINING  ENGINE UPDATE  EucoHIV  Phylogeotool  EuResist Mentor School  HCV European database - Pepsi  Funding opportunities

EIDB  Presently more than 65000 patients  New structure allows to store different pathogens (Hep) and sequences from different genomic regions  DB management moved from IBM to Koeln  Update ongoing  In the last two years 2 studies paid by Pharma and 5 scientific studies finalised + 2 ongoing  Could be better exploited

Engine retraining  The EuResist Engine has been trained in 2010 on a database with 48.000 patients and compared favourably with all existing GISS  Now it is old:  Short time point (8-12 weeks)  Unsatisfactory behaviour with newer drugs  Retraining needed

Engine retraining  Retraining is ongoing:  On much larger and newer data set (the present EIDB)  With longer time point (48 weeks)  Lower VL definition for failure: <50 copies per ml  Same structure and prediction answer: which combination therapy will minimise resistance  It will be fit for middle income and emerging countries

Engine update  Update is ongoing:  New prediction answer: how long will the patient remain aviremic  Collaboration among MPS (Alejandro Pironti) EuResist (Mattia Prosperi) and IBM (Tal El Hay) Other issues may be important: toxicity, pill burden, cost… Clinicians’ comments highly welcome!

EucoHIV  Data collection completed: 1470 patients  Study proposals are welcome!

Phylogeotool  From the EucoHIV activities - realised by KuLeuven group  Will be trained also on the EIDB and offered on the EuResist Engine website  Skype demo at 4:30 pm today Clinicians’ comments highly welcome! Lemey et al. 2009

EuResist Mentor School  Multidisciplinary course on value and usage of structured data  Addressed to young clinicians and researchers  Will offer an overview of existing databases and will train the pupils on how to formulate a scientifically sound question and how to write a query  Based on an extract from EIDB  2 days residential course with follow up possibly leading to publications  First mid of 2016 Comments highly welcome!

European HCV DB - PEPSI  PEPSI is funded from the German Ministry of Science and Education (BMBF) within the „Deutsches Zentrum für Infektiologische Forschung“, TTU Hepatitis  Andrea De Luca, Maurizio Zazzi and Saleta Sierra Aragon, Rolf Kaiser performed data evaluation on HCV 1a clade I and II for Italy and Germany (Open Forum in Infectious Diseases, accepted)  We will promote the project through the EURESIST partners and rise PEPSI on a European level

Industrial leadership /LEITs / Biotec Phase 1 and Phase 2 18/03/2015 17/06/2015 17/09/2015 25/11/2015

Societal Challenges / Health (SC1) / Personalising Health and Care 18/03/2015 18/03/2015 17/06/2015 17/06/2015 17/09/2015 17/09/2015 25/11/2015 25/11/2015

Eurostars supports research-performing small and medium enterprises , which develop innovative products, processes and services, to gain competitive advantage. Eurostars provides funding for transnational innovation projects, the products of which are then rapidly commercialized. To be eligible, the project can address any technology area , but must have a civilian purpose and be aimed at the development of a new product, process or service. • Consortium leader is an R&D performing SME from a Eurostars country • At least one other independent participant from another Eurostars country • The project duration is 3 years or fewer • Market introduction is within 2 years of the project’s completion…

"Improved treatment and clinical management of poverty-related diseases" Close date: moved to 16 June 2015, 17:00 Among the encouraged topics of this Call for Proposals: • Projects that aim to evaluate new or significantly improved drugs or drug regimens in humans or to optimise the efficacy and use of existing therapeutics for any of the PRDs, including co-infections of PRDs. •Two-stage application procedure: Stage 1 (Letter of Intent) Opening date: 28 January 2015 Deadline for submission: 16 April 2015 - moved to 16 June 2015

http:/ / w w w .euresist.org http:/ / engine.euresist.org Contact: f.incardona@inform acro.info Thank you

Innovative Medicines Initiative 2 (IMI 2)